BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8555506)

  • 21. Quantitation of the proliferative potential of highly enriched human primitive hematopoietic progenitor cells using a stroma-free limiting dilution assay with automated scoring.
    Young JC; Wu S; Travis M; Luens KM; Osborne L; Scollay R; Hill B
    Cytotherapy; 1999; 1(2):147-56. PubMed ID: 19746592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
    Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J
    Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
    Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M
    Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primitive multilineage progenitor cells predominate in peripheral blood early after mobilization with high-dose cyclophosphamide and GM-CSF or G-CSF.
    Croockewit S; Raymakers R; Trilsbeek C; Dolstra H; Pennings A; de Witte T
    Leukemia; 1994 Dec; 8(12):2194-9. PubMed ID: 7528861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells.
    To LB; Haylock DN; Dowse T; Simmons PJ; Trimboli S; Ashman LK; Juttner CA
    Blood; 1994 Nov; 84(9):2930-9. PubMed ID: 7524760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
    Facon T; Harousseau JL; Maloisel F; Attal M; Odriozola J; Alegre A; Schroyens W; Hulin C; Schots R; Marin P; Guilhot F; Granena A; De Waele M; Pigneux A; Méresse V; Clark P; Reiffers J
    Blood; 1999 Aug; 94(4):1218-25. PubMed ID: 10438709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Lynch JC; Atkinson K; Juttner C; Hanania CE; Bociek G; Armitage JO
    Biol Blood Marrow Transplant; 2001; 7(12):680-7. PubMed ID: 11787531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
    Pilarski LM; Belch AR
    Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing the CD34+ and CD34+Thy-1+ stem cell content of peripheral blood collections.
    Stewart AK; Imrie K; Keating A; Anania S; Nayar R; Sutherland DR
    Exp Hematol; 1995 Dec; 23(14):1619-27. PubMed ID: 8542956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating stem cell collection in lymphoma and myeloma after mobilization with cyclophosphamide and granulocyte colony-stimulating factor for autologous transplantation.
    Cancelas JA; Hernández-Jodra M; Zamora C; Perez-Oteyza J; Brieva JA; Roldan E; Navas G; Garcia-Laraña J; Lopez J; Odriozola J
    Vox Sang; 1994; 67(4):362-7. PubMed ID: 7535498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
    Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
    Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
    Gazitt Y; Akay C; Thomas C
    Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progenitor cell yield in sequential blood stem cell mobilization in the same patients: insights into chemotherapy dose escalation and combination of haemopoietic growth factor and chemotherapy.
    Lie AK; Rawling TP; Bayly JL; To LB
    Br J Haematol; 1996 Oct; 95(1):39-44. PubMed ID: 8857936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells.
    Haas R; Möhle R; Pförsich M; Fruehauf S; Witt B; Goldschmidt H; Hunstein W
    Blood; 1995 Apr; 85(7):1936-43. PubMed ID: 7535595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
    Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
    Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
    Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mobilization of circulating hematopoietic stem cells by granulocyte colony stimulating factor after chemotherapy in multiple myeloma].
    Ohler L; Scholten C; Reiter E; Tiefengraber E; Jäger U; Strobl H; Lechner K; Höcker P; Geissler K
    Wien Klin Wochenschr; 1993; 105(20):580-4. PubMed ID: 7505076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation.
    Danylesko I; Sareli R; Varda-Bloom N; Yerushalmi R; Shem-Tov N; Magen H; Shimoni A; Nagler A
    Int J Hematol; 2021 Sep; 114(3):363-372. PubMed ID: 34213732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.